We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

73 hedge funds and large institutions have $474M invested in Blueprint Medicines in 2015 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 18 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

9,855% more call options, than puts

Call options by funds: $19.6M | Put options by funds: $197K

61% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 18

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

44% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 9

4% more funds holding

Funds holding: 70 → 73 (+3)

7% less capital invested

Capital invested by funds: $509M → $474M (-$35.3M)

Holders
73
Holders Change
+3
Holders Change %
+4.29%
% of All Funds
1.92%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
13
Increased
29
Reduced
18
Closed
9
Calls
$19.6M
Puts
$197K
Net Calls
+$19.4M
Net Calls Change
+$19.4M

Top Buyers

Rank Fund Capital Flow
1
Fidelity International
Fidelity International
Bermuda
+$18.1M
2
BI
BVF Inc
California
+$13M
3
BFA
BlackRock Fund Advisors
California
+$7.4M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$6.5M
5
PI
Putnam Investments
Massachusetts
+$5.5M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$17.8M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$12.4M
3
Citadel Advisors
Citadel Advisors
Florida
-$9.22M
4
SM
Sabby Management
Florida
-$6.95M
5
RG
Redmile Group
California
-$2.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
26
Ameriprise
Minnesota
$2.94M +$521K +23,145 +26%
Northern Trust
27
Northern Trust
Illinois
$2.91M +$95.2K +4,227 +4%
CAM
28
Cormorant Asset Management
Massachusetts
$2.63M – – –
Goldman Sachs
29
Goldman Sachs
New York
$2.47M +$1.89M +84,099 +874%
Citigroup
30
Citigroup
New York
$2.24M +$195K +8,668 +11%
JP Morgan Chase
31
JP Morgan Chase
New York
$2.09M -$276K -12,273 -13%
Alyeska Investment Group
32
Alyeska Investment Group
Illinois
$1.96M -$217K -9,633 -11%
Geode Capital Management
33
Geode Capital Management
Massachusetts
$1.84M +$38.1K +1,694 +2%
NC
34
NBW Capital
Massachusetts
$1.18M -$75.5K -3,354 -7%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$1.06M +$290K +12,887 +47%
BIM
36
BlackRock Investment Management
Delaware
$862K +$4.12K +183 +0.6%
TCIM
37
TIAA CREF Investment Management
New York
$835K – – –
Morgan Stanley
38
Morgan Stanley
New York
$809K +$71.8K +3,189 +12%
TI
39
Trexquant Investment
Connecticut
$762K +$651K +28,914 New
Charles Schwab
40
Charles Schwab
California
$659K +$14.6K +650 +3%
ARTA
41
A.R.T. Advisors
New York
$645K +$551K +24,491 New
ProShare Advisors
42
ProShare Advisors
Maryland
$610K +$521K +23,157 New
AllianceBernstein
43
AllianceBernstein
Tennessee
$543K +$117K +5,200 +34%
PIM
44
Partner Investment Management
California
$475K +$178K +7,898 +78%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$458K +$8.15K +362 +2%
Mackenzie Financial
46
Mackenzie Financial
Ontario, Canada
$382K +$326K +14,500 New
Swiss National Bank
47
Swiss National Bank
Switzerland
$374K +$320K +14,200 New
TA
48
Teachers Advisors
New York
$359K – – –
WJA
49
Williams Jones & Associates
New York
$346K -$231K -10,250 -44%
TD Asset Management
50
TD Asset Management
Ontario, Canada
$345K – – –
1
2
3 4

BPMC Hedge Fund Activity: Q4 2015 in Review

73 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q4 2015, worth a combined $474M — down 6.9% from $509M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new BPMC positions and 9 closed out — a net gain of 4 holders — while 29 added to existing stakes and 18 trimmed.

The largest buyer was Fidelity International, opening a new position worth an estimated $18.1M. The largest seller was Wellington Management Group, cutting an estimated $17.8M.

  • 73 institutional investors held Blueprint Medicines (BPMC) as of Q4 2015, up from 70 in Q3 2015.
  • Funds reported $474M of Blueprint Medicines stock for Q4 2015, down 6.9% quarter-over-quarter.
  • 13 funds opened new Blueprint Medicines positions in Q4 2015 and 9 closed out, a net change of +4 holders.
  • The largest Blueprint Medicines buyer in Q4 2015 was Fidelity International, an estimated $18.1M added.
  • The largest Blueprint Medicines seller in Q4 2015 was Wellington Management Group, an estimated $17.8M sold.

Based on aggregated 13F filings for Q4 2015.